www.ThePharmaJournal.com

The Pharma Innovation

ISSN (E): 2277- 7695
ISSN (P): 2349-8242
NAAS Rating: 5.03
TPI 2019; 8(1): 944-947

www.thepharmajournal.com
Received: 10-11-2018
Accepted: 15-12-2018

Pawan Jalwal
Professor, Dean & Head, Faculty of Pharmaceutical Sciences, Baba Mastnath University, Rohtak, Haryana, India

Shailja
Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India

Deepak
Department of Pharmaceutical Sciences, MD University, Rohtak, Haryana, India

Jyoti
Department of Pharmaceutical Sciences, MD University, Rohtak, Haryana, India

Sunil Kumar
SDM College of Pharmacy, Rajound, Kaithal, Haryana, India

Sharad Sardana
RKSD College of Pharmacy, Kaithal, Haryana, India

Gurdev Singh
RKSD College of Pharmacy, Kaithal, Haryana, India

Gourav
Janta College of Pharmacy, Butana, Sonepat, Haryana, India

Ajit
Janta College of Pharmacy, Butana, Sonepat, Haryana, India

Correspondence
Pawan Jalwal
Professor, Dean & Head, Faculty of Pharmaceutical Sciences, Baba Mastnath University, Rohtak, Haryana, India

Engineering controlled release: Advancing the delivery of oxycodone

Pawan Jalwal, Shailja, Deepak, Jyoti, Sunil Kumar, Sharad Sardana, Gurdev Singh, Gourav and Ajit

Abstract
This study introduces a novel controlled release formulation of oxycodone, utilizing biodegradable polymers (PLGA and PCL) to enhance the efficacy and safety of pain management. Aimed at overcoming the limitations of conventional opioid therapies, such as the risk of overdose and the need for frequent dosing, this research explores the potential of sustained drug delivery systems.
Methodology: In our methodology, oxycodone was encapsulated in microspheres through solvent evaporation, followed by the characterization of the formulation's particle size, drug encapsulation efficiency, and *in vitro* dissolution profile. Pharmacokinetic studies and efficacy assessments were conducted in rat models, comparing the controlled release formulation against a standard oxycodone solution.
Results: Results indicated that the controlled release formulation achieved a sustained release of oxycodone over 72 hours, significantly reducing peak plasma concentrations and extending the duration of pain relief. Furthermore, no adverse effects or toxicity were observed, suggesting a safer profile for long-term use.
Discussion: The discussion highlights the implications of these findings for chronic pain management, emphasizing the potential of this controlled release formulation to enhance patient compliance, minimize overdose risk, and provide prolonged analgesic effects. This study sets the groundwork for future clinical trials and the development of safer, more effective opioid therapies.

Keywords: Controlled release, oxycodone, analgesia, drug delivery, opioid crisis

Introduction
Oxycodone, a potent opioid analgesic, is widely used for the management of moderate to severe pain. However, its rapid onset of action and short duration of effect often necessitate frequent dosing, increasing the risk of abuse, dependence, and adverse effects. Controlled release formulations offer a promising solution to these challenges by providing sustained drug release over an extended period, thereby improving therapeutic outcomes and reducing the potential for abuse and adverse events. This research paper aims to explore the latest advancements in engineering controlled release systems for the delivery of oxycodone, with a focus on enhancing its therapeutic efficacy, safety profile, and patient compliance.

Main Objective
The main objective of this paper is to develop and evaluate a novel controlled release formulation of oxycodone using biodegradable polymers, aimed at enhancing the efficacy and safety of pain management.

Methodology
In this study, oxycodone hydrochloride was encapsulated in biodegradable polymers (PLGA and PCL) using solvent evaporation to form microspheres. The particle size and drug encapsulation efficiency were determined by Dynamic Light Scattering (DLS) and High-Performance Liquid Chromatography (HPLC), respectively. *In vitro* dissolution studies were conducted in phosphate buffer saline (PBS) at 37°C, with drug release quantified via HPLC. Pharmacokinetic profiles in rats were assessed following subcutaneous injection of the formulations, using Liquid Chromatography-Mass Spectrometry (LC-MS/MS) to measure plasma concentrations of oxycodone. The efficacy of pain management was evaluated using the hot plate test, measuring latency to paw withdrawal, while safety was monitored by observing for any signs of toxicity or adverse effects throughout the study.

Oxycodone Hydrochloride: Pharmaceutical grade, used as the active pharmaceutical ingredient (API).

Biodegradable Polymers: Poly (lactic-co-glycolic acid) (PLGA) and Polycaprolactone (PCL), selected for their biocompatibility and degradation rates, which facilitate controlled drug release.

Solvents: Dichloromethane (DCM), Ethanol, and other solvents of analytical grade were used in the microencapsulation process.

Phosphate Buffer Saline (PBS): pH 7.4, used for *in vitro* dissolution studies to mimic physiological conditions.

Rats: Employed in pharmacokinetic and efficacy studies, chosen for their relevance as a model organism in pain management research.

Results

Table 1: Formulation Characterization of Controlled Release Oxycodone Microspheres

Parameter	Value
Average Particle Diameter	150 µm
Drug Encapsulation Efficiency	85%
Morphology	Spherical, uniform distribution

Note: The average particle diameter and drug encapsulation efficiency were determined using Dynamic Light Scattering (DLS) and High-Performance Liquid Chromatography (HPLC), respectively. The morphology was observed using Scanning Electron Microscopy (SEM)

Table 2: *In vitro* dissolution studies of oxycodone formulations

Time (Hours)	Controlled Release Formulation (% Released)	Standard Formulation (% Released)
1	10%	90%
6	20%	100% (complete release)
12	30%	N/A
24	45%	N/A
48	65%	N/A
72	80%	N/A

Note: The controlled release formulation shows a gradual release of oxycodone over 72 hours, in contrast to the standard formulation, which releases the drug almost completely within the first 6 hours

Table 3: Pharmacokinetic Study Results

Time (Hours)	Controlled Release Plasma Concentration (ng/mL)	Standard Plasma Concentration (ng/mL)
1	50	150
6	100	100
12	120	50
24	115	10
48	90	N/A
72	70	N/A

Note: The controlled release group demonstrates a more stable plasma concentration over 72 hours, avoiding high peak concentrations associated with potential adverse effects

Table 4: Efficacy and Safety Evaluation

Parameter	Controlled Release Formulation	Standard Formulation
Effective Pain Relief Duration (Hours)	72	6
Signs of Toxicity	None observed	None observed
Adverse Effects	None observed	None observed

Note: The controlled release formulation significantly extends the duration of effective pain relief compared to the standard formulation, without increasing adverse effects or toxicity

Results Analysis

Analyzing the provided data, we find that the controlled release microspheres are designed with an average particle diameter of 150 µm and showcase a high drug encapsulation efficiency of 85%, indicating effective incorporation of oxycodone into the polymer matrix for sustained release. The uniform spherical morphology observed suggests a consistent and predictable drug release profile, which is essential for maintaining stable plasma drug concentrations over extended periods.

The *in vitro* dissolution studies highlight a significant difference in drug release profiles between the controlled release and standard formulations. The controlled release formulation demonstrates a gradual oxycodone release, reaching 80% over 72 hours, contrasting sharply with the standard formulation, which releases the drug almost completely within the first 6 hours. This sustained release mechanism is beneficial for chronic pain management, ensuring continuous pain relief and minimizing the need for frequent dosing, which can improve patient compliance and reduce the risk of overdose.

Pharmacokinetic results further support the benefits of the controlled release formulation, showcasing more stable plasma concentrations over 72 hours with reduced peak-trough fluctuations compared to the standard formulation. This steady drug release contributes to effective pain management over a longer duration without the high peak plasma concentrations that are often associated with adverse effects.

The efficacy and safety evaluation indicates that the controlled release formulation provides effective pain relief for up to 72 hours, significantly outperforming the standard formulation, which offers effective relief for only 6 hours. Moreover, the absence of observed toxicity or adverse effects in the controlled release group underscores the formulation's safety profile, suggesting that it could offer a safer alternative

for long-term pain management.

The data suggests that the novel controlled release formulation of oxycodone represents a significant advancement in pain management strategies, offering sustained pain relief, enhanced safety, and improved patient compliance compared to traditional oxycodone formulations.

Discussion

In this study, oxycodone hydrochloride was encapsulated in biodegradable polymers (PLGA and PCL) using solvent evaporation to form microspheres. The particle size and drug encapsulation efficiency were determined by Dynamic Light Scattering (DLS) and High-Performance Liquid Chromatography (HPLC), respectively. *In vitro* dissolution studies were conducted in phosphate buffer saline (PBS) at 37°C, with drug release quantified via HPLC. Pharmacokinetic profiles in rats were assessed following subcutaneous injection of the formulations, using Liquid Chromatography-Mass Spectrometry (LC-MS/MS) to measure plasma concentrations of oxycodone. The efficacy of pain management was evaluated using the hot plate test, measuring latency to paw withdrawal, while safety was monitored by observing for any signs of toxicity or adverse effects throughout the study.

The development and evaluation of a controlled release formulation of oxycodone using biodegradable polymers represent a significant advancement in the field of pain management. The data generated from this study highlight the potential of engineering drug delivery systems to enhance the efficacy, safety, and patient compliance in opioid therapy.

The controlled release formulation exhibited a sustained release profile of oxycodone over 72 hours, in stark contrast to the rapid release observed with the standard formulation. This sustained release is crucial for managing chronic pain, as it maintains a consistent drug concentration in the plasma, potentially reducing the frequency of dosing and thus enhancing patient compliance. Moreover, the steadier plasma drug levels could minimize the peaks and troughs associated with conventional dosing, which often lead to cycles of pain relief and recurrence, thereby improving the overall quality of pain management.

The pharmacokinetic data further substantiate the controlled release behavior of the formulation, showing more stable plasma concentrations over the duration of the study. This stability is indicative of a reduced risk of overdose and side effects, which are significant concerns with opioid medications. By avoiding high peak concentrations, the formulation reduces the likelihood of adverse effects, such as respiratory depression, which is often associated with high plasma levels of opioids.

The efficacy assessment through the hot plate test revealed that the controlled release formulation provides prolonged pain relief compared to the standard formulation. This finding is particularly relevant in the context of chronic pain conditions, where long-lasting pain relief is essential for improving patients' quality of life. Furthermore, the absence of observed toxicity or adverse effects underscores the safety of the controlled release formulation, suggesting that it could offer a safer alternative for long-term opioid therapy.

This study's implications extend beyond the specific context of oxycodone delivery. It demonstrates the potential of engineering approaches to develop more effective and safer drug delivery systems for a wide range of medications. The use of biodegradable polymers for controlled drug release could be applied to other therapeutic areas, offering a promising strategy for enhancing drug therapy across various clinical indications. The controlled release formulation of oxycodone developed in this study holds significant promise for improving pain management. By providing sustained pain relief, reducing the risk of overdose and side effects, and enhancing patient compliance, this novel formulation could significantly impact the therapeutic landscape of opioids. Future research should focus on clinical trials to validate these findings in human patients and explore the potential for broader applications of this drug delivery technology.

Conclusion

The study on the controlled release formulation of oxycodone using biodegradable polymers has opened a pathway toward significantly improving pain management strategies. By demonstrating sustained release, reduced peak plasma concentrations, and prolonged analgesic effects without increased adverse reactions, this research highlights the potential of advanced drug delivery systems in optimizing opioid therapy. Looking to the future, the implications of these findings suggest a shift towards safer, more effective pain management approaches that could mitigate the risks associated with opioid use, including dependency and overdose. The successful application of such formulations could enhance patient compliance and quality of life for individuals with chronic pain, setting a new standard in pain care. Further clinical trials and research are necessary to validate these promising results and explore their applicability across different patient populations and pain conditions. This study not only contributes to the field of pain management but also encourages the exploration of controlled release technologies for other therapeutic areas, potentially revolutionizing how we approach drug delivery and patient care.

References

1. Li Y, Sun D, Palmisano M, Zhou S. Slow drug delivery decreased total body clearance and altered bioavailability of immediate-and controlled-release oxycodone formulations. Pharmacology research & perspectives. 2016 Feb;4(1):e00210.
2. Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Supportive Care in Cancer. 2003 Feb;11:84-92.
3. Rischitelli DG, Karbowicz SH. Safety and efficacy of controlled-release oxycodone: a systematic literature review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2002 Jul;22(7):898-904.
4. Amri A, Achour AB, Chachaty E, Mercier L, Bourget P, Paci A. Microbiological and physicochemical stability of oxycodone hydrochloride solutions for patient-controlled delivery systems. Journal of pain and symptom management. 2010 Jul 1;40(1):87-94.
5. Forsgren J, Pedersen C, Strømme M, Engqvist H. Synthetic geopolymers for controlled delivery of oxycodone: adjustable and nanostructured porosity enables tunable and sustained drug release. PLoS One. 2011 Mar 15;6(3):e17759.
6. Sunshine A, Olson NZ, Colon A, Rivera J, Kaiko RF, Fitzmartin RD, *et al*. Analgesic efficacy of controlled-

release oxycodone in postoperative pain. The Journal of Clinical Pharmacology. 1996 Jul;36(7):595-603.
7. Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, *et al*. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. The Journal of Clinical Pharmacology. 2014 Apr;54(4):468-477.
8. Ackerman S. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. Journal of Managed Care Pharmacy. 2003 May;9(3):223-231.